GreenLight Biosciences Holdings
GRNA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $4 | $3 | $2 | $2 |
| % Growth | 29.6% | 74.5% | -3.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $3 | $2 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $23 | $32 | $30 | $44 |
| G&A Expenses | $9 | $9 | $8 | $10 |
| SG&A Expenses | $9 | $9 | $8 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $32 | $41 | $38 | $54 |
| Operating Income | -$28 | -$39 | -$36 | -$52 |
| % Margin | -740.6% | -1,321.4% | -2,145.5% | -2,972.5% |
| Other Income/Exp. Net | -$0 | $0 | -$1 | $0 |
| Pre-Tax Income | -$28 | -$39 | -$37 | -$52 |
| Tax Expense | -$0 | $1 | $1 | -$0 |
| Net Income | -$28 | -$40 | -$38 | -$52 |
| % Margin | -734.1% | -1,356.6% | -2,259.2% | -2,968.6% |
| EPS | -0.18 | -0.3 | -0.27 | -0.42 |
| % Growth | 40% | -11.1% | 35.7% | – |
| EPS Diluted | -0.18 | -0.3 | -0.27 | -0.42 |
| Weighted Avg Shares Out | 152 | 132 | 139 | 123 |
| Weighted Avg Shares Out Dil | 152 | 132 | 139 | 123 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $3 | $4 | $2 | $0 |
| EBITDA | -$25 | -$35 | -$34 | -$51 |
| % Margin | -663.7% | -1,194.1% | -2,027.2% | -2,890.8% |